Sea Moss for Juvenile Idiopathic Arthritis: Anti-Inflammatory, T-Cell/IL-17/TNF Pediatric Joint Autoimmunity & Mineral Support

Juvenile idiopathic arthritis (JIA) is the most common chronic pediatric rheumatic disease (~1/1,000 children), encompassing 7 ILAR subtypes — oligoarticular (most common, 50%, ANA+, uveitis risk), polyarticular RF-negative, polyarticular RF-positive (RA-equivalent), systemic (sJIA, IL-1beta/IL-6/S100 macrophage activation), enthesitis-related (ERA, HLA-B27/IL-17A), psoriatic JIA, and undifferentiated — all driven by Th1/Th17 dysregulation, TNF-alpha/IL-6/IL-1beta NF-kB cascades, RANKL-mediated bone erosion, and MMP-driven cartilage destruction. Sea moss fucoidan modulates NF-kB, IL-6, and TNF-alpha cascades; selenium supports chondrocyte and synoviocyte GPx1/4; zinc supports FOXP3+ Treg and growth plate repair; omega-3 modulates LTB4/PGE2 synovial eicosanoids; calcium/magnesium support developing bone matrix. MTX, NSAIDs, TNF inhibitors (etanercept, adalimumab), IL-6R (tocilizumab), IL-1 (anakinra/canakinumab for sJIA), and JAK inhibitors are standard.

Read the full guide